Latest Regulatory Approval News

Australian Strategic Materials (ASM) has announced a revised timetable for its shareholder scheme meetings tied to Energy Fuels’ acquisition, alongside dispatching a supplementary booklet that updates key transaction details including a new expert report. The acquisition now contemplates Energy Fuels’ conditional US$725 million financing and a US$1.9 billion deal to acquire VAC.

Lake Resources has raised A$3.8 million through an at-the-market placement priced above recent trading levels, earmarked for environmental and power optimisation work at its Kachi lithium project.

Firebrick Pharma expanded its patent portfolio with grants in Canada and New Zealand while achieving 43% sales growth in FY26 despite steady operating expenses. The company is advancing Nasodine's commercial rollout across Southeast Asia and the US.

EQT AB’s controlled entity has raised its indicative offer for Perpetual to A$22.50 per share, a modest increase contingent on the sale of Perpetual’s Wealth Management business and other conditions. The Perpetual Board remains undecided and has not recommended shareholder action.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

Bannerman Energy advances Etango uranium project with early works on track and CNNC Overseas Limited investment nearing completion, targeting a positive Final Investment Decision in Q3 2026.

Prodigy Gold’s latest scoping study for the Hyperion Gold Project outlines a viable open pit operation with a 260,000-ounce production target and strong financial metrics. Meanwhile, exploration funding and ore sorting advances at Old Pirate support near-term development prospects.

Astral Resources has boosted its Mandilla Gold Project resource to 1.74 million ounces of gold, with drilling confirming significant mineralisation and the Definitive Feasibility Study progressing towards completion in early 2027.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

GoldArc Resources has discovered two major gold mineralisation corridors exceeding 600 metres at its Yttria prospect, expanding beyond its existing rare earth element resource and setting the stage for follow-up drilling.

Capricorn Metals has transformed its Mt Gibson Gold Project with a new underground mine, lifting annual production to 260,000 ounces and extending mine life to over 19 years, backed by a robust $6.1 billion NPV.

Mamba Exploration has completed its acquisition of a 70% stake in the Meeka East Gold Project, identified over 20km of gold anomalies through soil sampling, and secured $90,000 in government co-funding for an upcoming drilling program.